NEURALINK

Institutional Archetype

THE ADMIN LAYER — Neuralink is the party that sits between a person’s motor cortex and the machine it drives. An implanted brain-computer interface holds four powers at once over the signal it reads: it records what the electrodes capture, it transmits that capture off the skull, it can push a firmware update to a computer wired into living tissue, and — because the device belongs to a company — it is the custodian of the decoded neural data if that company is bought, sold, or dissolved. In ordinary computing the single party that holds all four powers is called root. This profile scores that structural position — the mechanism of single-party custody over a signal the subject cannot retract — not the medicine, which is real, and not the motives of anyone at the company, which the record cannot settle. The signal read off the cortex, decoded, and transmitted is not corrigible the way speech is: a post can be deleted, a statement walked back; a decoded neural recording, once held by someone else, was never in the speaker’s keeping to begin with. The hazard is the custody, not the cure.

Mandate & Origin

Neuralink was founded on 21 June 2016 by Elon Musk and a founding team of eight scientists and engineers (Max Hodak, Benjamin Rapoport, Dongjin Seo, Paul Merolla, Philip Sabes, Tim Gardner, Tim Hanson, and Vanessa Tolosa), headquartered in Fremont, California. Its stated purpose is to build an implantable brain-computer interface that returns autonomy to people with unmet medical needs — beginning with digital independence for people with quadriplegia, and extending, per the company, to “control of robotic arms, wheelchairs, and other technologies.” The FDA granted an Investigational Device Exemption in May 2023; the first human implant was performed on 28 January 2024 at Barrow Neurological Institute in Phoenix, in Noland Arbaugh, a man paralyzed below the shoulders since a 2016 diving accident. The device is the N1 implant — 1,024 electrodes on 64 flexible threads, inserted into the motor cortex by the R1 surgical robot; intention becomes electrode capture, on-chip digitization, a Bluetooth hop, and an ML decoder trained on the individual’s neural patterns, which turns the signal into cursor motion.

Funding & Backers

Neuralink is a privately held company funded principally by Elon Musk. By 2019 it had received $158 million in funding, of which $100 million was Musk’s own; it has raised further private rounds since and remains Musk-controlled, outside public-market disclosure. The relevant non-cash backing is regulatory: beyond the 2023 IDE, the FDA has granted Neuralink Breakthrough Device Designations — for Blindsight (vision restoration) in September 2024 and for speech restoration in May 2025. A breakthrough designation grants prioritized FDA review and faster expert interaction during premarket review; it is expressly not an approval and not a safety or efficacy finding — a distinction routinely lost in the coverage, which reports the tag as if the agency had blessed a permanent cortical implant for general use.

Institutional Voice & Intent

Neuralink’s register is the trial update: first-person plural, participant-forward and numeric. The company describes itself in one sentence: “Neuralink is building brain-computer interfaces (BCI) that will return autonomy to people with unmet medical needs” (Neuralink, Two Years of Telepathy). Its clinical-trials page states the goal as “Advance brain-computer interfaces through rigorous, evidence-based research to safely increase independence and broaden access to this technology,” and carries the standing disclaimer: “Neuralink devices are investigational and have not been approved by the FDA or other regulatory authorities” (Neuralink, Clinical Trials). Participants are given the front of the page (“Through Neuralink, I found work. Just writing that sentence almost brought me to tears,” says Noland, listed as a participant with spinal cord injury), and the company calls them Neuralnauts: “a growing crew of 21 Neuralnauts enrolled in trials worldwide” (same pages). The vocabulary is restoration; the one sentence that leaves it is in the funding announcement:

• On direction. The $650 million Series E announcement says the money “will accelerate our efforts to expand patient access and innovate future devices that deepen the connection between biological and artificial intelligence” (Neuralink, Series E). The same post lists, among advances since 2023, “Progressing towards a whole-brain interface” (same page).
• On data. The company’s privacy policy (last updated March 12th, 2025) says: “We do not sell your personal information or share personal information with third parties for targeted advertising purposes.” Its list of permitted disclosures includes “Business transfers. We may disclose your personal information to acquiring and other relevant parties to business transactions (or potential transactions) involving a corporate divestiture, merger, consolidation, acquisition, reorganization, sale or other disposition of all or any portion of the business or assets of, or equity interests in Neuralink” (Neuralink, Privacy Policy).
• On where the implant’s data is governed. The same policy says: “our privacy practices in connection with clinical trials are governed by applicable clinical trial protocol(s) and related informed consents and, where applicable, HIPAA authorization forms” (same page). The trial consents are not published; the two consent forms on the site are for the Patient Registry in Canada and the UK (Neuralink sitemap).
• On derived data. The policy lists a purpose “To create anonymized and/or aggregated data sets (i.e., that we cannot link back to any individual) that may be used for a variety of functions, including internal analysis, analytics, and other functions”; the Patient Registry notice adds “We may use this anonymized information for internal research and product development, or any other legal purpose” (Neuralink, Patient Registry Privacy Notice).
• On pace. The most recent entry on the updates page (1 October 2026) is headed “Pretraining on 50,000 Hours of Unlabeled Brain Data” and described as “How self-supervised encoders kept neural decoders working for weeks without recalibration and set an 11.32 BPS record” (Neuralink, Updates).

Stated intent: Restore autonomy to people with unmet medical needs, beginning with device control for people with quadriplegia and extending to speech and vision, through “rigorous, evidence-based research” (Neuralink, Clinical Trials).

Observed intent: A multi-indication, multi-country trial network financed by a $650 million round with 49 investors on the Form D, an FDA breakthrough-designation strategy for two further indications, and, from registrations posted on 29 May and 1 June 2026, two retained federal lobbying firms whose filings list “Issues related to Medicare coverage and reimbursement pathways for breakthrough medical devices” (SEC, Neuralink Corp. Form D filed 2025-06-12; LDA, Arnold & Porter Q3 2026).

Gap: The stated test is clinical evidence; the observed program also builds the payment and policy position for the device before any approval. Neither contradicts the other. What the public record leaves open is the term that matters most to the archetype: who holds the decoded neural data after a sale. The privacy policy names business transfers as a permitted disclosure for the data it covers; the document that would govern implant data, the trial informed consent, is not on the site.

• Social accounts and feeds. X @neuralink, LinkedIn company page, Facebook, Instagram and YouTube @neuralink, all linked from the footer of neuralink.com; no feed: neuralink.com/feed, /rss.xml and /updates/rss.xml return 404, so the updates page is the publication.

Position in the Apparatus

Neuralink sits at the seam between a medical-device regulator, a payer and a data custodian, and it holds none of those seats. It is a sponsor: the party that writes the protocol, runs the implant and keeps the signal.

• The trial network. ClinicalTrials.gov lists Neuralink Corp as lead sponsor of six studies: PRIME (NCT06429735; start 9 January 2024; Barrow Neurological Institute and the University of Miami; enrollment listed as 15), a Barrow device-control study (NCT06710626; 3), CAN-PRIME (NCT06700304; University Health Network, Canada; 6), UAE-PRIME (NCT06992596; Cleveland Clinic Abu Dhabi; 10), GB-PRIME (NCT07127172; University College London Hospitals and Newcastle upon Tyne Hospitals; 7) and VOICE (NCT07224256; UT Southwestern; “Communication Restoration”; 6) (ClinicalTrials.gov, search for Neuralink; PRIME). The sites are the hospitals that supply surgeons and review boards; the sponsor supplies everything else.
• The regulator. FDA describes its Breakthrough Devices Program as “a voluntary program for certain medical devices” for “life-threatening or irreversibly debilitating diseases,” and says “Breakthrough Devices must meet the FDA’s rigorous standards for device safety and effectiveness” (FDA, Breakthrough Devices Program). Neuralink’s own trials page says its devices “have not been approved by the FDA or other regulatory authorities.” FDA does not publish individual investigational device exemption decisions; the May 2023 IDE rests on Neuralink’s statements and the reporting already cited on this page.
• The payer. Two lobbying firms report Neuralink as a client. Arnold & Porter Kaye Scholer lists “Issues related to access to medical devices, including neurotechnology/brain-computer interface products” and “Issues related to Medicare coverage and reimbursement pathways for breakthrough medical devices,” with contacts in the House, the Senate, the Office of Management and Budget, the White House Office and, in the second quarter, the Centers for Medicare and Medicaid Services; Jeffrey J. Kimbell & Associates lists “Issues related to the development and commercialization of brain-computer interfaces” and “Issues related to coverage of medical devices” (LDA, Arnold & Porter Q3 2026; Arnold & Porter Q2 2026; Kimbell Q3 2026). A coverage pathway is the rule that turns an investigational device into a reimbursed one, and the company that lobbies for it is the company that would be reimbursed. That is a documented interest in the position, not a finding about anyone’s motive.
• The capital. Neuralink’s five Form D filings since 2017 report amounts sold of $26,958,000 (2017), $39,312,497 (2019), $205,899,985 (2021), $323,241,676 (2023, amended in November from an August filing of $280,274,981) and $649,000,093 (2025, 49 investors), which sum to $1,244,412,251. Elon Musk is listed as an executive officer on the 2021, 2023 and 2025 filings and Jared Birchall as an executive officer and director on all five; Max Hodak is listed as an executive officer in 2019 (SEC EDGAR, Neuralink Corp., CIK 1708503). The 2025 round’s investors, as Neuralink names them, are “ARK Invest, DFJ Growth, Founders Fund, G42, Human Capital, Lightspeed, QIA, Sequoia Capital, Thrive Capital, Valor Equity Partners, Vy Capital, amongst others” (Neuralink, Series E).
• The comparison set. The firms that share the body-layer position are on The Body-Layer Firms; the data-custody question as it applies to a cortical implant is on Neuralink and brain data and The Body Layer. The custody precedent set by 23andMe in bankruptcy is the one a neural-data holder would be measured against.

Actions & Leadership Choices

The register is medical restoration. The deeds, read end to end, describe a genuine clinical advance operated by a single private custodian of the most intimate capture surface yet built — and the deeds support the admin-layer frame the archetype names.

The restoration is real, and it is the reason the custody matters. Arbaugh set an early human cursor-control record and, by his own account, uses the implant to work, study, game, and communicate; in Neuralink’s published participant quote he says the Link “has helped me reconnect with the world, my friends, and my family… without needing my family at all hours.” This is not a strawman capability. It is precisely because the device is a miracle — because miracles get adopted, and adoption is scale — that the question of who holds root on it stops being abstract.

• The firmware power was demonstrated on the first patient. Within weeks of surgery a number of the electrode threads retracted from Arbaugh’s brain tissue, cutting effective channels and degrading performance; press reporting (NBC, Popular Science, later the Wall Street Journal) put the retraction near 85%, a figure Neuralink acknowledged the retraction but never itself published. The fix was software, not surgery: engineers rewrote the decoder to extract more signal from the surviving electrodes, and performance recovered. That is an honest engineering response — and it is the admin-layer motif made literal. The same power that repaired the device from outside the skull is the power to change, from outside, how a device behaves inside a person’s brain. There is no maintainable implant that does not also grant it.

• The custody question is already sourced to named experts. Neuroethicists have criticized Neuralink on the record — for announcing results by social media rather than peer review and for the trial’s registration handling (Marcello Ienca, TU Munich; L. Syd M Johnson, SUNY Upstate; Laura Cabrera, Penn State) — and University of Washington professors Nancy S. Jecker and Andrew Ko have laid out the standing concerns: neural-data privacy, third-party manipulation of autonomy, device abandonment after a study ends, and access inequality. These are the on-record hooks for the capture frame; they are the book’s synthesis over attributed expert concern, never a claim that Neuralink is doing these things.

• The install base is small; the custody model is not. Neuralink reported 21 trial participants worldwide as of January 2026, with trials in the US, Canada, the UK, and the UAE, and Musk has stated an intent to move to “high-volume” production in 2026 (industry read: hundreds toward low thousands per year). The gap between the rhetoric and the install base is itself the point: the custody arrangement — one private party holding record, transmit, update, and inheritance rights over decoded cortical data — is fixed now, at 21 people, before the scale it is built for arrives.

CONDUCT: ROOT-ON-THE-BRAIN — IRREVERSIBLE NEURAL CAPTURE UNDER SINGLE-PARTY CUSTODY. Neuralink does real, consented, restorative medicine — and it is structurally the single party that records from inside the skull, transmits what it reads, can rewrite the device from outside, and would inherit the decoded neural data in any sale. The signal is not retractable; the custody is not shared. The cure is genuine; the position is root. Compare the data-custody edge at 23andMe (genetic database as bankruptcy asset), the biometric-key custody at Worldcoin and Clearview AI, and the downstream aggregation at Palantir.

Alliance Map

These run at the same time. A company with an investigational device and no approval raised $649 million in 2025, ran trials in four countries, hired two federal lobbying firms in 2026 whose filings put Medicare coverage for breakthrough devices on the list, and, in its own privacy policy, reserves the right to disclose personal information in a sale of the business. Each piece is disclosed by Neuralink, an investor filing or a lobbying registrant; the overlap is the finding.

Reach Assessment

Institutional: A device sponsor with a growing trial network, a capital base measured in the hundreds of millions per round, and a seat in the federal coverage conversation through two registered lobbying firms. Memetic: The product name “Telepathy” and the participant narrative, which the company publishes in the participants’ own words, are the public face of brain-computer interfaces. Civilizational: The custody structure is set while the install base is small: one private party holds the record, transmit, update and, under the business-transfers clause of its policy, potentially the sale rights for the data it covers.

Counted: 21 participants enrolled worldwide as of 28 January 2026 on the company’s count (Neuralink, Two Years of Telepathy); six Neuralink-sponsored studies on ClinicalTrials.gov across the United States, Canada, the United Arab Emirates and the United Kingdom; $1,244,412,251 reported sold in five Form D offerings between 2017 and 2025; $140,000 of lobbying income reported by the two firms for Neuralink in the third quarter of 2026. The hazard is the structure, not any act: an irreversible implant, a single operator, a data-governance document that is not public.

The competitors: Precision Neuroscience (founded by a Neuralink co-founder) and the clearance its surface implant actually has are on The Body-Layer Firms.

Sources: Neuralink — PRIME Study Progress Update: User Experience; Neuralink — Two Years of Telepathy (2026-01-28); Neuralink — Breakthrough Device Designation for Speech (2025-05-01); Neuralink — Wikipedia; NBC News — Neuralink implant suffers setback after threads retract; Popular Science — 85% of Neuralink implant wires detached; Forbes — Experts Criticize Neuralink Over Transparency (2024-02-26); The Conversation — Two professors unpack Neuralink’s ethical issues; The Debrief — Neuralink Reaches 21 Patients.